Professional Marketing briefs

Manhattan Research has released the latest version of its ePharma Physician v11.0 study, which indicates that since June 2011, 38% of the physicians polled have seen a sales rep use an iPad or other tablet during a face-to-face meeting over the course of the past year. The study's findings also suggest that marketers have yet to optimize the interactive features and capabilities of tablet devices to achieve the most efficient and customized discussion with physicians about their products, and verify that Pfizer, AstraZeneca, Merck and Abbott make up big-name pharmas leading the way in terms of iPad reach via sales reps.

Working to merge interactivity and personalization on tablet devices, Kaon Interactive has launched Kaon v-OSK, an HD touch-screen appliance that delivers interactive messages via website, laptop and mobile devices. Users can explore the medical devices and investigate features, controlling their customized experiences based on personal preferences. 

InfoMedics has furthered the expansion of its sales force with the appointment of Charles Andrews as VP, US pharmaceutical sales. Previously he was director, strategic accounts at WebMD, after having spent 10 years at BMS and GSK in a variety of key senior roles. 









You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.